Liraglutide shows limited efficacy for weight loss in obese French adolescents, with 55% achieving some reduction
Background
Adolescent obesity is a chronic and complex condition, influenced by genetic mechanisms affecting appetite regulation via the hypothalamus, compounded by environmental factors. Current curative treatments, primarily restrictive diets, are challenging to maintain long-term. While GLP-1 analogues have shown efficacy in adults, their specific impact and tolerability in obese adolescents without diabetes, particularly within a French population, remain underexplored. This gap highlights the need for effective pharmacotherapeutic alternatives.
Study Design
This single-center, observational study evaluated the efficacy and tolerance of liraglutide in 20 obese, non-diabetic adolescents in France. The specific dose, route, and duration of liraglutide administration were not detailed in the abstract. Researchers assessed overall weight loss as a primary efficacy endpoint, alongside changes in body composition, specifically fat mass. Patient tolerance was monitored through reported adverse events, with gastrointestinal side effects being a key focus. The study did not include a control arm, focusing on a real-world cohort analysis.
Results
Overall efficacy of liraglutide in this cohort of obese adolescents was lower than anticipated and below previously published findings. Eleven patients (55%) experienced some weight loss, but only 3 patients (15%) achieved a significant weight reduction of >5%. However, among the 12 patients whose body composition was measured, 7 of them (58%) lost at least 5% of their fat mass, suggesting a potential benefit in body composition despite modest overall weight loss. Tolerability was a significant concern: > 65% of patients experienced gastrointestinal side effects, including nausea, vomiting, and diarrhea. These adverse events were severe enough to lead to treatment discontinuation in 20% of the participants. The study concluded that liraglutide's efficacy in this specific population was poor.
Despite limited overall weight loss, 58% of adolescents with body composition data lost at least 5% of their fat mass.
Key Findings
- Only 55% of obese adolescents treated with liraglutide experienced some weight loss.
- Just 15% of patients achieved a clinically significant weight loss of >5%.
- Among those with body composition data, 58% lost at least 5% of their fat mass.
- Gastrointestinal side effects were reported by 65% of patients.
- Side effects led to treatment discontinuation in 20% of patients.
Why It Matters
This study underscores that liraglutide's efficacy in obese adolescents may be less pronounced than in adults, suggesting that current GLP-1 protocols might require significant optimization for younger populations. The finding of fat mass reduction despite modest overall weight loss is a critical nuance, indicating potential metabolic benefits that aren't fully captured by scale weight alone. For clinicians and biohackers, this implies that while GLP-1s remain a promising class, a 'one-size-fits-all' approach is insufficient for adolescents. Future protocols for adolescent obesity may need to prioritize compounds with better tolerability profiles or explore combination therapies to achieve clinically meaningful weight loss while minimizing side effects that lead to discontinuation.
liraglutide
adolescent-obesity
weight-loss
glp-1-agonist
gastrointestinal-side-effects
preclinical-animal